OR WAIT null SECS
The HERS trial was the first study to put a damper on enthusiasm for hormone replacement therapy (HRT) as a preventive therapy for heart disease. A second trial called ERA (Estrogen Replacement and Atheriosclerosis trial), reported at the 49th Annual Meeting of the American College of Cardiology, held in Anaheim, California, March 12–15, 2000, provides additional evidence that HRT does not prevent heart disease.
Data Presented from The 49th Annual Meeting of the American College of Cardiology
March 12–15, 2000/Anaheim, California
Re-printed with permission of C 2000 Millennium Medical Communications, Inc.
This report was reviewed for medical and scientific accuracy by William H. Stuart, MD, Medical Director, Multiple Sclerosis Center at Shepherd Center; Medical Director, Center for Rehabilitation Medicine, Piedmont Hospital, Atlanta, Georgia; Chairman, HealthMed Advisory Board, webhealthsearch.com
The HERS trial was the first study to put a damper on enthusiasm for hormone replacement therapy (HRT) as a preventive therapy for heart disease. A second trial called ERA (Estrogen Replacement and Atheriosclerosis trial), reported at the 49th Annual Meeting of the American College of Cardiology, held in Anaheim, California, March 12–15, 2000, provides additional evidence that HRT does not prevent heart disease. The study implies that women with existing heart disease should not take HRT with the goal of preventing the advancement of their heart condition. ERA also suggests that women and their physicians should rely on medications already proven to prevent heart disease, such as cholesterol-lowering drugs like the statins, which have a dramatic effect on decreasing the risk of heart attacks and death.
"This study shows that HRT may not be as effective as we once thought in slowing heart disease," said David Herrington, MD, MDS, of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. He added that women and their doctors should make full use of therapies proven to prevent heart disease, such as the statins and other cholesterol-lowering drugs.
The ERA study included 309 older women, at an average age of 65-years-old, with heart disease who were randomly assigned to take Premarin® (estrogen), Prempro® (estrogen combined with a progestin), or a dummy pill (placebo). A sophisticated computerized technique called quantitative coronary angiography was used to measure any changes in their arteries due to treatment; the changes that were assessed included the build-up of cholesterol that causes narrowing of the arteries and can lead to chest pain and heart attack.
After a mean follow-up of 3.2 years, all three groups demonstrated the same rate of narrowing of the coronary vessels. Therefore, neither estrogen alone (Premarin®) nor estrogen combined with a progestin (Prempro®) changed the course of disease compared to no active treatment at all (placebo pill).
It should be emphasized that the women included in this study all had heart disease and were at a high risk for progression of heart disease when they entered the study. The average age of the women was 65 years. Approximately half of the women had already had a prior heart attack, about half had been treated with balloon angioplasty (another procedure used to open the clogged arteries), at least one quarter had diabetes, at least 60 percent had hypertension, about 18 percent were cigarette smokers, and more than 55 percent were overweight.
Dr. Herrington noted that the study was performed in older, less healthy women and therefore does not reflect what effects hormone therapy might have on preventing heart disease in younger, healthier women. However, the two studies done to date to assess the effects of HRT on the heart suggest that there is no protective effect against the advancement of heart disease. Younger, healthier women who wish to prevent heart disease are advised to eat a heart-healthy diet, exercise regularly, and not to smoke cigarettes.
This Report is a product of Millennium Medical Communications, Inc. ("MMC, Inc."), an independent, third-party organization providing educational information concerning current medical data and opinions presented at worldwide medical meetings. This Report is published in accordance with the Guidance for Industry: Industry Supported Scientific and Educational Activities, 62 Fed. Reg. 64,093, 64,096-99 (1997) adopted by the U.S. Department of Health and Human Services Food and Drug Administration. Pursuant to the foregoing standards, MMC, Inc. is solely responsible for selecting the topics discussed herein as well as the guest editor. The ideas and opinions expressed by the guest editor are those solely of the guest editor and do not necessarily reflect the opinions of Millennium Medical Communications, Inc. or any Sponsor hereto. This Report may contain data on products, product uses, indications, and dosages, which are not approved for use in the USA, Canada and the European Union and no endorsement is hereby made or intended by coverage of any unapproved use. The content of this report is intended for educational purposes only, and merely conveys scientific data presented at medical meetings. Approved product labeling should always be consulted for prescribing information. This Report is an independent and non-promotional report intended to provide accurate scientific and medical information for educational purposes. MMC, Inc. is not responsible for errors or omissions in reports. The production of this report was paid for by MMC, Inc.
Â© 2000 Millennium Medical Communications, Inc.
Millennium Medical Communications
Bridget R. Dupuis, RN, BSN
Director of Business Development
(603) 929-5078 x 109